<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180106038234N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-12</date_registration>
      <primary_sponsor>Bagheiat-allah University of Medical Sciences</primary_sponsor>
      <public_title>Therapeutic Effectiveness of Mulligan Mobilization with Movement on Pain, Functional Mobility and Balance, and Spatiotemporal Gait Parameters in people with Knee Osteoarthritis: A Randomized Clinical Trial</public_title>
      <acronym></acronym>
      <scientific_title>Therapeutic Effectiveness of Mulligan Mobilization with Movement on Pain, Functional Mobility and Balance, and Spatiotemporal Gait Parameters in people with Knee Osteoarthritis: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93966</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this trial, 40 eligible participants will be randomly allocated to either the intervention group (MWM+CSE) or the control group (CSE alone) in a 1:1 ratio. A block randomization method with a fixed block size of 4 will be used to ensure balanced allocation between the two groups throughout the recruitment period. Each block will contain 2 participants for the intervention group and 2 participants for the control group. The randomization sequence will be generated by an independent statistician who will not be involved in recruitment, assessment, or intervention delivery. A computer-based random number generator, such as Random Allocation Software, will be used to produce the sequence.

Allocation concealment will be ensured using opaque, sequentially numbered, sealed envelopes (SNOSE method). The envelopes will be stored securely and will be opened only after baseline assessments have been completed. The envelopes will be opened by a person who is not involved in the treatment team. This procedure will prevent selection bias and ensure that group allocation remains concealed until the moment of assignment.

The outcome assessor and data analyst will be blinded to group allocation. Participants and treating physiotherapists will not be blinded because of the nature of the intervention, Blinding description: This trial will be a single-blind study. The outcome assessor and the data analyst will be blinded to group allocation. Participants, the clinical care provider (treating physiotherapist), the principal investigator, and the Data Safety and Monitoring Committee will not be blinded. Participants will be fully informed that they are participating in a randomized controlled trial and will provide written informed consent. Blinding of participants will be impractical because of the nature of the intervention (manual therapy versus no manual therapy). The outcome assessor will be independent from the treatment team and will perform all measurements without knowledge of group allocation. The data analyst will analyze the data using coded labels, and the allocation code will be revealed only after the analysis is completed. Allocation concealment will be ensured using opaque, sequentially numbered, sealed envelopes (SNOSE method).</study_design>
      <phase>N/A</phase>
      <hc_freetext>knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention group: Participants will receive Mulligan Mobilization with Movement followed by Core Stability Exercises. Mulligan Mobilization with Movement will be applied by a single physiotherapist using standardized glides (lateral, medial, or rotational) based on pain-free range improvement. The technique will involve a sustained, pain-free manual glide force to the proximal tibia near the knee joint with a counterforce applied to the femur. The direction of the glide will be chosen based on the movement that results in the greatest improvement in pain-free mobility. While maintaining the sustained glide, participants will be instructed to actively move their affected knee within a pain-free range, either towards flexion or extension. Each session will involve three sets of six to ten repetitions of the most effective technique. In addition, participants will receive moist heat therapy for 15 minutes and a structured core stability exercise program for 20 to 25 minutes, including pelvic bridging, resisted knee flexion, resisted knee extension, mini squats, and heel raises. Participants will also perform a home program of brisk walking for 20 minutes daily on non-clinical days. The intervention will last for 4 weeks, with 12 sessions, three sessions per week, each session lasting 45 minutes..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No further information is available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ehsan Ebrahimipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Biomechanics Department, Faculty of Physical Education and Sport Sciences, Shahid Bahonar University of Kerman, Kerman, Iran</address>
        <city>kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7612748901</zip>
        <telephone>0098342719234</telephone>
        <email>ehsan94324001@gmail.com</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ehsan Ebrahimipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Biomechanics Department, Faculty of Physical Education and Sport Sciences, Shahid Bahonar University of Kerman, Kerman, Iran</address>
        <city>kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7615289340</zip>
        <telephone>0098342719234</telephone>
        <email>ehsan94324001@gmail.com</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1 Participants will be female or male
2 Participants will be aged 50 to 75 years
3 Participants will have bilateral medial compartment knee osteoarthritis
4 The osteoarthritis will be classified as Kellgren/Lawrence grade three
5 Participants will have chronic knee pain for at least 3 months
6 Pain intensity will be moderate (VAS 4–8/10)
7 The diagnosis will be confirmed by an orthopedic specialist
8 The diagnosis will be based on American College of Rheumatology criteria
9 Participants will be referred to physiotherapy and orthopedic outpatient departments of University of Medical Sciences of Kerman hospitals</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1 History of knee surgery (arthroplasty, ligament reconstruction, or meniscectomy)
2 Lower limb fracture within less than 6 months
3 Neurological or musculoskeletal conditions impairing mobility
3 Neurological or musculoskeletal conditions impairing mobility
5 Contraindications to manual therapy (joint instability, acute infection, malignancy)
6 Uncontrolled hypertension (BP &gt;160/100 mmHg)
7 Cardiovascular limitations
8 Radiating leg pain suggesting radiculopathy
9 BMI &gt;40 kg/m²
10 Recent intra-articular injections within less than 6 months
11 Current physiotherapy or exercise programs
12 Inability to perform basic functional tasks (standing from chair unassisted, walking 10 m, or lying prone)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants will receive Mulligan Mobilization with Movement followed by Core Stability Exercises. Mulligan Mobilization with Movement will be applied by a single physiotherapist using standardized glides (lateral, medial, or rotational) based on pain-free range improvement. The technique will involve a sustained, pain-free manual glide force to the proximal tibia near the knee joint with a counterforce applied to the femur. The direction of the glide will be chosen based on the movement that results in the greatest improvement in pain-free mobility. While maintaining the sustained glide, participants will be instructed to actively move their affected knee within a pain-free range, either towards flexion or extension. Each session will involve three sets of six to ten repetitions of the most effective technique. In addition, participants will receive moist heat therapy for 15 minutes and a structured core stability exercise program for 20 to 25 minutes, including pelvic bridging, resisted knee flexion, resisted knee extension, mini squats, and heel raises. Participants will also perform a home program of brisk walking for 20 minutes daily on non-clinical days. The intervention will last for 4 weeks, with 12 sessions, three sessions per week, each session lasting 45 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before the intervention and after the intervention period of 4 weeks. Method of measurement: Knee Injury and Osteoarthritis Outcome Score, VAS.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Functional mobility measured by Timed Up and Go test. Timepoint: Before the intervention and after the 4-week intervention period. Method of measurement: Timed Up and Go test, measuring the time to rise from a standard chair, walk three meters, turn, return, and sit down; average of three trials.</sec_outcome>
      <sec_outcome>Walking endurance measured by Six-Minute Walk Test. Timepoint: Before the intervention and after the 4-week intervention period. Method of measurement: Six-Minute Walk Test, measuring the maximum distance walked in six minutes along a straight 30-meter walkway.</sec_outcome>
      <sec_outcome>Postural Stability Index in static balance. Timepoint: Before the intervention and after the 4-week intervention period. Method of measurement: Biodex Balance System, static platform condition, eyes open and eyes closed, three trials of 30 seconds each.</sec_outcome>
      <sec_outcome>Gait spatio-temporal parameters. Timepoint: Before the intervention and after the 4-week intervention period. Method of measurement: Three-dimensional motion analysis system with six infrared cameras and passive reflective markers based on the Plug-in-Gait model, walking along an 8-meter walkway at self-selected comfortable speed, three valid trials.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bagheiat-allah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-17</approval_date>
        <contact_name>Research Ethics Working Group/Committee, Baqiyatallah Al-A’zam (AJ) Educational and Medical Center</contact_name>
        <contact_address>Vanak Square, Molla Sadra Street, Sheikh Bahaei Street, Baqiyatallah University of Medical Sciences (AJ) Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
